Table 1.

Comparison of TNBCs: basal-like vs. nonbasal

	Triplenegative:nonbasal	Triplenegative:basal-like
Basal-like markers:
CK 5/6 and/or EGFR-positive by IHC	No (47.4%)	Yes (52.6%) (17)
CK 5/6, CK14, CK17,and/or EGFR-positiveby IHC	No (28.9%)	Yes (71.1%) (18)
Basal-like gene profile	No (28.5%)	Yes (71.5%) (14)
p53 positive by IHC	41.0%	62.0% (18)
Distant metastasis, 10-yrfollow-up	26.0%	37.0% (18)
Breast cancer-specific survival, 10-yr follow-up	71.6% 75.5%	62.2% (17) 56.6% (18)

IHC, Immunohistochemistry; CK, cytokeratin.